These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Momelotinib in myelofibrosis: JAK1/2 inhibitor with a role in treating and understanding the anemia. Winton EF; Kota V Future Oncol; 2017 Feb; 13(5):395-407. PubMed ID: 27785927 [TBL] [Abstract][Full Text] [Related]
3. MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. Verstovsek S; Chen CC; Egyed M; Ellis M; Fox L; Goh YT; Gupta V; Harrison C; Kiladjian JJ; Lazaroiu MC; Mead A; McLornan D; McMullin MF; Oh ST; Perkins A; Platzbecker U; Scheid C; Vannucchi A; Yoon SS; Kowalski MM; Mesa RA Future Oncol; 2021 Apr; 17(12):1449-1458. PubMed ID: 33423550 [TBL] [Abstract][Full Text] [Related]
4. A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis. Gupta V; Mesa RA; Deininger MW; Rivera CE; Sirhan S; Brachmann CB; Collins H; Kawashima J; Xin Y; Verstovsek S Haematologica; 2017 Jan; 102(1):94-102. PubMed ID: 27634203 [TBL] [Abstract][Full Text] [Related]
5. Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2. Harrison CN; Vannucchi AM; Recher C; Passamonti F; Gerds AT; Hernandez-Boluda JC; Yacoub A; Sirhan S; Ellis C; Patel B; Strouse B; Platzbecker U Adv Ther; 2024 Sep; 41(9):3722-3735. PubMed ID: 38990433 [TBL] [Abstract][Full Text] [Related]
6. SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis. Mesa RA; Kiladjian JJ; Catalano JV; Devos T; Egyed M; Hellmann A; McLornan D; Shimoda K; Winton EF; Deng W; Dubowy RL; Maltzman JD; Cervantes F; Gotlib J J Clin Oncol; 2017 Dec; 35(34):3844-3850. PubMed ID: 28930494 [TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Pardanani A; Gotlib J; Roberts AW; Wadleigh M; Sirhan S; Kawashima J; Maltzman JA; Shao L; Gupta V; Tefferi A Leukemia; 2018 Apr; 32(4):1035-1038. PubMed ID: 29263442 [No Abstract] [Full Text] [Related]
8. Momelotinib: Mechanism of action, clinical, and translational science. Vlasakakis G; McCabe MT; Ho YL; Ferron-Brady G; Martin P; Bentley D; Ellis C; Antonysamy M; Visser SAG Clin Transl Sci; 2024 Aug; 17(8):e70018. PubMed ID: 39189872 [TBL] [Abstract][Full Text] [Related]
9. Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. Harrison CN; Vannucchi AM; Platzbecker U; Cervantes F; Gupta V; Lavie D; Passamonti F; Winton EF; Dong H; Kawashima J; Maltzman JD; Kiladjian JJ; Verstovsek S Lancet Haematol; 2018 Feb; 5(2):e73-e81. PubMed ID: 29275119 [TBL] [Abstract][Full Text] [Related]
10. Momelotinib therapy for myelofibrosis: a 7-year follow-up. Tefferi A; Barraco D; Lasho TL; Shah S; Begna KH; Al-Kali A; Hogan WJ; Litzow MR; Hanson CA; Ketterling RP; Gangat N; Pardanani A Blood Cancer J; 2018 Mar; 8(3):29. PubMed ID: 29515114 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Pardanani A; Laborde RR; Lasho TL; Finke C; Begna K; Al-Kali A; Hogan WJ; Litzow MR; Leontovich A; Kowalski M; Tefferi A Leukemia; 2013 Jun; 27(6):1322-7. PubMed ID: 23459451 [TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. Verstovsek S; Courby S; Griesshammer M; Mesa RA; Brachmann CB; Kawashima J; Maltzman JD; Shao L; Xin Y; Huang D; Bajel A Leuk Res; 2017 Sep; 60():11-17. PubMed ID: 28622623 [TBL] [Abstract][Full Text] [Related]
13. Momelotinib for the treatment of myelofibrosis with anemia. Tremblay D; Mesa R Future Oncol; 2022 Jun; 18(20):2559-2571. PubMed ID: 35603634 [TBL] [Abstract][Full Text] [Related]
14. Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trial. Gupta V; Oh S; Devos T; Dubruille V; Catalano J; Somervaille TCP; Platzbecker U; Giraldo P; Kosugi H; Sacha T; Mayer J; Illes A; Ellis C; Wang Z; Gonzalez Carreras FJ; Strouse B; Mesa R Leuk Lymphoma; 2024 Jul; 65(7):965-977. PubMed ID: 38501751 [TBL] [Abstract][Full Text] [Related]
15. Investigational Janus kinase inhibitors in development for myelofibrosis. Bose P; Abou Zahr A; Verstovsek S Expert Opin Investig Drugs; 2017 Jun; 26(6):723-734. PubMed ID: 28441920 [TBL] [Abstract][Full Text] [Related]
16. Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. Verstovsek S; Gerds AT; Vannucchi AM; Al-Ali HK; Lavie D; Kuykendall AT; Grosicki S; Iurlo A; Goh YT; Lazaroiu MC; Egyed M; Fox ML; McLornan D; Perkins A; Yoon SS; Gupta V; Kiladjian JJ; Granacher N; Lee SE; Ocroteala L; Passamonti F; Harrison CN; Klencke BJ; Ro S; Donahue R; Kawashima J; Mesa R; Lancet; 2023 Jan; 401(10373):269-280. PubMed ID: 36709073 [TBL] [Abstract][Full Text] [Related]